Navigation Links
Review Finds Marijuana May Help MS Patients
Date:12/4/2009

However, benefits are not clear enough to recommend its use, experts say ,,

FRIDAY, Dec. 4 (HealthDay News) -- Cancer patients, glaucoma patients and others can benefit from medical marijuana, and now a new analysis shows that it can help multiple sclerosis (MS) patients find relief from the muscle spasms that are the hallmark of the debilitating autoimmune disease.

"The therapeutic potential of cannabinoids in MS appears to be comprehensive, and should be given considerable attention," said lead researcher Dr. Shaheen Lakhan, executive director of the Global Neuroscience Initiative Foundation.

"Spasticity, an involuntary increase in muscle tone or rapid muscle contractions, is one of the more common and distressing symptoms of MS," the researchers noted in their review. "Medicinal treatment may reduce spasticity, but may also be ineffective, difficult to obtain or associated with intolerable side effects," they added.

"We found evidence that cannabis plant extracts may provide therapeutic benefit for MS spasticity symptoms," Lakhan said.

Although some objective measures showed improvement, there were no significant changes in after-treatment assessments, Lakhan said. "However, subjective assessment of symptom relief did often show significant improvement post-treatment," he added.

For the study, Lakhan and his colleague Marie Rowland reviewed six studies where marijuana was used by MS patients. Five of the trials showed that marijuana reduced spasms and improved mobility, according to the report published Dec. 3 in the online journal BMC Neurology.

Specifically, the studies evaluated the cannabis extracts delta9-tetrahydrocannabinol (THC) and cannabidiol (CBD). These studies found that both THC and CBD extracts may provide therapeutic benefit for MS spasticity symptoms, Lakhan said.

Although there was a benefit from using marijuana there were also side effects, such as intoxication. This varied depending on the amount of marijuana needed to effectively limit spasms, but side effects were also seen in the placebo groups, Lakhan and Rowland noted.

The careful monitoring of symptom relief and side effects is critical in reaching an individual's optimal dose, Lakhan said. "Moreover, there is evidence that cannabinoids may provide neuroprotective and anti-inflammatory benefits in MS," he added.

"Considering the distress and limitations spasticity brings to individuals with MS, it would be important to carefully weigh the potential for side effects with the potential for symptom relief, especially in view of the relief reported in subjective assessment," Lakhan said.

Dr. Moses Rodriguez, a professor of neurology and immunology at the Mayo Clinic, said that "the idea of using cannabis to treat MS has been around for a long time."

Rodriguez noted that the effects of using marijuana have been mixed. "It has been difficult to know whether the effect has been just a general well-being or whether it has a direct effect on muscle fibers and spasticity," he said.

If drugs could be developed that take away the intoxicating effects of marijuana, it could have a direct effect on spasms without the high, Rodriguez said.

The Obama administration announced in October that it will no longer prosecute medical marijuana users or suppliers, provided they obey the laws of states that allow use of the drug for medicinal purposes.

Rodriguez said he is often asked by his MS patients about whether there is a benefit to using marijuana.

"What I tell my patients," he said, "is if they want to try it they should try it. They should understand that there is a potential for it to be habit-forming and there may be a potential that they are fooling themselves."

Patricia A. O'Looney, vice president of biomedical research at the National Multiple Sclerosis Society, said the society has studied this issue and does not think enough is known to recommend that MS patients use marijuana.

"Because the studies to date do not demonstrate a clear benefit compared to existing therapy, and issues of side effects and long-term effects are not clear, the recommendation is that it should not be recommended at this time," she said.

Another expert, Dr. William Sheremata, director of the Multiple Sclerosis Center at the University of Miami School of Medicine, also doesn't think MS patients necessarily benefit from marijuana use.

Sheremata noted that the objective measures in the study did not show any benefit from marijuana. "Those are the only valid measures. Subjective responses are subjective; they really don't have much in the way of validity," he said. "I am not convinced that the use of marijuana benefits patients as a whole."

More information

For more information on multiple sclerosis, visit the National Multiple Sclerosis Society.



SOURCES: Shaheen Lakhan, M.D., Ph.D., executive director, Global Neuroscience Initiative Foundation, Panorama City, Calif.; Moses Rodriguez, M.D., professor, neurology and immunology, Mayo Clinic, Rochester, Minn.; Patricia A. O'Looney, Ph.D., vice president, biomedical research, National Multiple Sclerosis Society, New York City; William Sheremata, M.D., director, Multiple Sclerosis Center, University of Miami School of Medicine; Dec. 3, 2009, BMC Neurology, online


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Targeted Testing Receives Favorable Reviews On PADDS, Begins Nationwide Research Study On The Target Tests of Executive Functioning-OV
2. The Attorneys of The Onder Law Firm Offers Free XOLAIR Case Review
3. Reportlinker Adds Imaging Agents - A Worldwide Market Review
4. Reportlinker Adds Cosmetic Surgery Procedures and Products - A US and European Market Review
5. Last-resort lower-body amputation effective in extreme cases of bone infection, 25-year review shows
6. XOLAIR Safety Study Continues to 2012 Despite Increased Rate of Occurrence of Heart Problems, Onder Law Firm Offers Free XOLAIR Case Review
7. Yaz and Yasmin Birth Control Lawsuits Continue to Mount The Onder Law Firm Will Provide a Free Case Review to Women Suffering from Yaz Side Effects
8. The Quigley Corporation to Host Conference Call to Review Third Quarter Results and Provide Company Update
9. NAMI Applauds Initial Review of The Affordable Health Care of America Act and Health Care Reform
10. Regence Takes Community Approach to Provider Reviews
11. External Evidence-Based Reviews Keep Healthcare System Vital
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... ... January 21, 2017 , ... Pacifica Graduate Institute’s Alumni Association ... of events for its annual meeting “Coming Home 2017,” an activity-packed weekend of ... 2017” will be held on Friday January 27 through Sunday, January 29, 2017 ...
(Date:1/21/2017)... ... , ... In the United States, 20 million women and 10 million men ... feel shame for having struggled with an eating disorder as well as common co-occurring ... in Life After an Eating Disorder” -- to be featured at this year’s iaedp ...
(Date:1/20/2017)... ... ... A new partnership between Goodwill® and Roadie, Inc. aims to make it ... to couches to dressers and bicycles. Roadie — the national on-the-way delivery network — ... center through February 28th. , “January is an exciting time when resolutions are ...
(Date:1/20/2017)... Boca Raton, FL (PRWEB) , ... January 20, 2017 , ... ... supplement development, announced it attended the January ECRM trade show to continue the marketing ... technologically advanced vitamin C supplement, known for providing 400 percent better absorption than traditional ...
(Date:1/20/2017)... , ... January 20, 2017 , ... ... products to enhance people’s everyday lives, recently attended the January ECRM Trade Show ... ATP Science is known for its large range of supplements that keep the ...
Breaking Medicine News(10 mins):
(Date:1/20/2017)... Avillion LLP, a co-developer and financier of late-stage pharmaceutical product candidates, ... Chief Medical Officer. Dr Weinberg will be based in ... ... 17 years as a pharmaceutical and biotech executive with experience ranging ... of his career, he has interfaced with the US Food & ...
(Date:1/19/2017)... -- Report Details What can be expected ... to grow at the fastest rates? This visiongain report ... opportunities and prospects. Our 190-page report provides 124 ... in the industry and the future market prospects. Our ... all the major categories of the ophthalmic devices market. ...
(Date:1/19/2017)... , Jan. 19, 2017 Conference Call and Webcast to ... ) today announced it will release results for the fourth quarter ... ... host a conference call at 4:30 PM ET on Wednesday, February ... full year 2016 financial results and other corporate activities. To participate ...
Breaking Medicine Technology: